SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. More Details
Flawless balance sheet with weak fundamentals.
Share Price & News
How has SpectraCure's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: SPEC has not had significant price volatility in the past 3 months.
7 Day Return
SE Medical Equipment
1 Year Return
SE Medical Equipment
Return vs Industry: SPEC underperformed the Swedish Medical Equipment industry which returned 11.7% over the past year.
Return vs Market: SPEC underperformed the Swedish Market which returned 9.5% over the past year.
Price Volatility Vs. Market
How volatile is SpectraCure's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 month ago | Simply Wall StCompanies Like SpectraCure (STO:SPEC) Can Afford To Invest In Growth
4 months ago | Simply Wall StWhat Kind Of Shareholder Appears On The SpectraCure AB (publ)'s (STO:SPEC) Shareholder Register?
5 months ago | Simply Wall StHere's Why We're Not Too Worried About SpectraCure's (STO:SPEC) Cash Burn Situation
Is SpectraCure undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate SPEC's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate SPEC's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: SPEC is unprofitable, so we can't compare its PE Ratio to the SE Medical Equipment industry average.
PE vs Market: SPEC is unprofitable, so we can't compare its PE Ratio to the Swedish market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate SPEC's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: SPEC is overvalued based on its PB Ratio (7.7x) compared to the SE Medical Equipment industry average (4.4x).
How is SpectraCure forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Healthcare industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as SpectraCure has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine SpectraCure's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- SpectraCure competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Healthcare industry.
How has SpectraCure performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: SPEC is currently unprofitable.
Growing Profit Margin: SPEC is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: SPEC is unprofitable, and losses have increased over the past 5 years at a rate of 23.2% per year.
Accelerating Growth: Unable to compare SPEC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPEC is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (18.4%).
Return on Equity
High ROE: SPEC has a negative Return on Equity (-7.5%), as it is currently unprofitable.
How is SpectraCure's financial position?
Financial Position Analysis
Short Term Liabilities: SPEC's short term assets (SEK184.0M) exceed its short term liabilities (SEK23.8M).
Long Term Liabilities: SPEC's short term assets (SEK184.0M) exceed its long term liabilities (SEK4.2M).
Debt to Equity History and Analysis
Debt Level: SPEC is debt free.
Reducing Debt: SPEC has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: SPEC has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: SPEC has sufficient cash runway for 2.3 years if free cash flow continues to reduce at historical rates of 27.5% each year.
What is SpectraCure current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate SPEC's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate SPEC's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if SPEC's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if SPEC's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of SPEC's dividend in 3 years as they are not forecast to pay a notable one for the Swedish market.
How experienced are the management team and are they aligned to shareholders interests?
Masoud Khayyami (57 yo)
Dr. Masoud Khayyami, Ph.D. is a Founder and serves as Manager at MK Capital AB. He serves as Chairman of the Board of Lumito AB (publ). He serves as the Chief Executive Officer at SpectraCure AB. He is a f ...
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 7.1%.
SpectraCure AB (publ)'s company bio, employee growth, exchange listings and data sources
- Name: SpectraCure AB (publ)
- Ticker: SPEC
- Exchange: OM
- Founded: 2003
- Industry: Health Care Equipment
- Sector: Healthcare
- Market Cap: kr1.591b
- Shares outstanding: 87.47m
- Website: https://www.spectracure.com
Number of Employees
- SpectraCure AB (publ)
- Gasverksgatan 1
- Skåne County
- 222 29
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|SPEC||OM (OMX Nordic Exchange Stockholm)||Yes||Share Capital||SE||SEK||Jul 2015|
|2OK||DB (Deutsche Boerse AG)||Yes||Share Capital||DE||EUR||Jul 2015|
SpectraCure AB (publ) focuses on cancer treatment utilizing laser light sources and photo reactive drugs. It develops IDOSE software with interstitial photodynamic therapy system, which is in Phase II clin ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/10/28 22:28|
|End of Day Share Price||2020/10/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.